Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Substance Withdrawal Syndrome 1Prostatic Neoplasms 1Overweight 1Obesity 1Melanoma 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Radiotherapy 3Carboplatin 3Trastuzumab 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2proto-oncogene protein c-fes-fps 1palbociclib 1gallium 68 PSMA-11 1fluciclovine F-18 1Vorinostat 1Thiotepa 1Taxes 1Tamoxifen 1Sugars 1Radiation 1Paclitaxel 1Naltrexone 1Melphalan 1Letrozole 1Fulvestrant 1Fluorine-18 1Drugs, Generic 1Doxorubicin 1Docetaxel 1Crizotinib 1Counseling 1Chemotherapy, Adjuvant 1Albumin-Bound Paclitaxel 168Ga-DKFZ-PSMA-11 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Lobular × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡